Alnylam Pharmaceuticals (NASDAQ:ALNY) will be announcing its earnings results before the market opens on Tuesday, August 6th. Analysts expect the company to announce earnings of ($2.06) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.20) by $0.47. Alnylam Pharmaceuticals had a negative return on equity of 55.33% and a negative net margin of 929.51%. The company had revenue of $33.29 million during the quarter, compared to analysts’ expectations of $21.60 million. During the same quarter in the previous year, the business earned ($1.22) earnings per share. The firm’s revenue for the quarter was up 52.0% on a year-over-year basis. On average, analysts expect Alnylam Pharmaceuticals to post $-8 EPS for the current fiscal year and $-8 EPS for the next fiscal year.
NASDAQ ALNY traded up $1.86 on Tuesday, reaching $77.49. The stock had a trading volume of 6,759 shares, compared to its average volume of 647,655. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.12 and a current ratio of 9.33. Alnylam Pharmaceuticals has a 12-month low of $60.27 and a 12-month high of $124.21. The company’s 50-day moving average is $72.98. The firm has a market capitalization of $8.06 billion, a PE ratio of -10.11 and a beta of 2.50.
A number of research firms have recently issued reports on ALNY. Stifel Nicolaus began coverage on SkyWest in a report on Monday, April 15th. They issued a “buy” rating and a $68.00 target price on the stock. Svb Leerink dropped their target price on Zogenix from $60.00 to $48.00 and set an “outperform” rating on the stock in a report on Tuesday, April 9th. BidaskClub lowered Xencor from a “sell” rating to a “strong sell” rating in a report on Tuesday, June 11th. BMO Capital Markets raised TMAC Resources from a “market perform” rating to an “outperform” rating in a report on Thursday, May 2nd. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $58.00 price objective on shares of Eagle Pharmaceuticals in a report on Monday, April 15th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $127.44.
In other news, CEO John Maraganore sold 49,457 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $70.00, for a total transaction of $3,461,990.00. Following the transaction, the chief executive officer now owns 239,450 shares in the company, valued at $16,761,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 3.60% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.